Opioid Abuse Treatment Claims Prompt FDA Warnings To Two Kratom Marketers
As in previous warnings to kratom supplement marketers linked to opioid addiction treatment claims, FDA tells Cali Botanicals and Kratom NC that HHS in 2017 found opioid abuse was nationwide public health emergency and FDA is targeting products that without approval claim to diagnose, mitigate, prevent, treat or cure opioid addiction. Contract manufacturer Somlabs' GMP problems also were identified in FDA's latest warning letters.
You may also be interested in...
CSPI says FDA has warned companies about tianeptine, which stimulates opioid receptors and may trigger addiction and withdrawal symptoms. But “tianeptine products continue to be widely available in Alabama and online.”
Therapeutic Solutions says animal study data show synergy in use of NanoStilbene, its proprietary formulation of pterostilbene, together with anti-CTLA4 antibody, "the mouse equivalent" of ipilimumab, an immunotherapeutic in the "checkpoint inhibitors" family of drugs. It also notes early results of clinical trial with cancer patients suggesting NanoStilbene efficacy in increased activity of immune system "natural killer" cells and enhanced production of interferon gamma, a protein associated with cancer growth suppression.
California changes Prop 65 reproductive-toxin averaging proposal; kratom group backs FDA enforcement on opioid treatment claims; oligosaccharides in goat milk formula show strong prebiotic, anti-pathogen adhesion properties; and CRN criticizes AARP-funded study on supplements and brain health as “inaccurate generalization.”